25 September 2025
Economic evaluation of HMG-CoA reductase inhibitors (statin) for primary prevention of cardiovascular diseases among Thai population (in Thai language)
View Count
45
Share this research
Project Code
01-308-2550
Country
Thailand
Project Duration
Start : 1 January 2007
Research Status
Completed 100%
Complete Research Report
Quantity 0 files
Download Count
0 times
25 September 2025
Economic evaluation of HMG-CoA reductase inhibitors (statin) for primary prevention of cardiovascular diseases among Thai population (in Thai language)
About Project
Content
The aims of this study were 1) to estimate the incremental cost-effectiveness ratio (ICER) of offering statins for primary prevention of CVD for each CVD risk group, and 2) to estimate the budget impact if the statins were prescribed to those people living with different CVD risks. This was a model-based economic evaluation. A Markov model was constructed to estimate the costs and benefits in terms of quality adjusted life year (QALY) gained by providing statins in comparison to a “null” or “do nothing” scenario. The study revealed that if a ceiling threshold is equal to 3 times that of Gross Domestic Product per capita or 300,000 Baht per QALY, a generic simvastatin is a cost-effective intervention for all people except those with less than 2.5% CV D risk. However, if the ceiling threshold is equal to 100,000 Baht per QAL Y, a generic simvastatin is still considered as a cost-effective intervention if it is offered to Thai people with > 30% CVD risk.
Research Type
Others
Related Technologies
Pharmaceuticals
Others
Funding Source
Strategy and Planning Division, Office of Permanent Secretary, Ministry of Public Health, Thailand
Research Team
Principal Researcher
Related Organizations/
Supporting Organizations
Strategy and Planning Division, Office of Permanent Secretary, Ministry of Public Health, Thailand